EGFR and non-small cell lung carcinoma: In this study, patients with EGFR-mutated NSCLC and a MET amplification as the resistance mechanism showed a much higher response rate (ORR) with the combination of osimertinib and tepotinib compared to tepotinib alone (54.5% [95% CI 32.2–75.6] vs. 8.3% [95% CI 0.2–38.5]) [28].